Lei Zhong is a dedicated researcher in the field of tumor pharmacology and pharmacogenomics, currently affiliated with the Personalized Drug Therapy Key Laboratory of Sichuan Province at the Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital in Chengdu, Sichuan, China. Lei completed a Ph.D. in Tumor Pharmacology from the State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu, and holds a Master of Science degree in Pharmaceutics from the West China School of Pharmacy, Sichuan University. Their research primarily focuses on small molecule targeted drugs, kinase inhibitors, tumor resistance mechanisms, cancer stem cells, pharmacodynamics, and therapeutic targets, with a particular interest in non-small cell lung cancer and gastrointestinal cancers.
Author Metrics
Scopus Profile
Lei Zhong’s contributions to the field are reflected in their author metrics, including citation count, h-index, and impact factor of the journals where their work is published. These metrics demonstrate the impact and significance of their research in advancing knowledge and understanding in tumor pharmacology and pharmacogenomics.
- Total citations: 1,569
- Total documents: 1,510
- Total number of documents authored: 61
- h-index: 20
This indicates that Lei Zhong has contributed to 61 documents that have been cited a total of 1,569 times, and their h-index is 20, which suggests that they have authored at least 20 papers that have each been cited at least 20 times.
Education
Lei Zhong pursued a Ph.D. in Tumor Pharmacology from the State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, Chengdu, China, from September 2012 to June 2015. Prior to this, they obtained a Master of Science degree in Pharmaceutics from the West China School of Pharmacy, Sichuan University, Chengdu, China, from September 2009 to June 2012.
Research Focus
Lei Zhong’s research focuses on tumor pharmacology and pharmacogenomics. Their work spans various aspects, including small molecule targeted drugs, kinase inhibitors, mechanisms of tumor resistance, cancer stem cells, pharmacodynamics, and therapeutic targets. They have a keen interest in exploring individualized drug therapies, particularly for non-small cell lung cancer and gastrointestinal cancers.
Professional Journey
Lei Zhong has had a diverse professional journey in academia and research. They have served as both an assistant and associate researcher at the Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital. Additionally, Lei undertook a postdoctoral program at Uppsala University in Sweden. Their research journey has been marked by continuous dedication to advancing the understanding and treatment of cancer through pharmacological interventions.
Honors & Awards
Lei Zhong has received several prestigious honors and awards for their outstanding contributions to the field of tumor pharmacology and pharmacogenomics. These include grants from various funding bodies such as the National Natural Science Foundation of China, the WU JIEPING Medical Foundation, and the General Financial Grant from the China Postdoctoral Science Foundation, among others.
Publications Top Noted& Contributions
Lei Zhong has made significant contributions to the scientific community through numerous publications in peer-reviewed journals. Their research covers a wide range of topics, including the role of histone methyltransferases in tumorigenesis, small molecule therapeutics for COVID-19, targeted cancer therapy, and the development of novel inhibitors for various cancers. Their work has been published in esteemed journals like Cancer Chemotherapy and Pharmacology, Frontiers in Pharmacology, and Signal Transduction and Targeted Therapy, among others.
Title: Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study
- Authors: Zhong, L., Zhao, Z., Zhang, X.
- Journal: Signal Transduction and Targeted Therapy
- Year: 2023
- Volume: 8
- Issue: 1
- Pages: 363
- Citations: 0
- Abstract: The paper likely explores genetic variances between primary and metastatic cancer through a comprehensive whole-genome comparison across various cancer types.
Title: Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells
- Authors: Lu, X., Zhong, L., Lindell, E., … Sjöblom, T., Zhang, X.
- Journal: Cell Death and Disease
- Year: 2023
- Volume: 14
- Issue: 10
- Pages: 676
- Citations: 0
- Abstract: This study likely identifies ATF3 as a protective signature associated with quiescent colorectal tumor cells.
Title: Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases
- Authors: Jiang, D., Xu, T., Zhong, L., … Xiao, W., Shi, J.
- Journal: European Journal of Medicinal Chemistry
- Year: 2023
- Volume: 257
- Pages: 115535
- Citations: 1
- Abstract: This paper may discuss the advancements in research regarding VEGFR small molecule inhibitors and their applications in ocular neovascular diseases.
Title: Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways
- Authors: Peng, X., Shi, J., Zhao, Z., … Zhang, X., Zhong, L.
- Journal: Cancer Chemotherapy and Pharmacology
- Year: 2023
- Volume: 91
- Issue: 4
- Pages: 303–315
- Citations: 4
- Abstract: This review article likely explores the anti-gastric cancer activity of emetine, a natural product, and its regulation of multiple signaling pathways.
Title: Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse
- Authors: Lindell, E., Zhong, L., Zhang, X.
- Journal: International Journal of Molecular Sciences
- Year: 2023
- Volume: 24
- Issue: 4
- Pages: 3762
- Citations: 4
- Abstract: This review article likely discusses the potential of quiescent cancer cells as a therapeutic target to overcome tumor resistance and relapse.
Research Timeline
Lei Zhong’s research timeline showcases their academic and professional journey, highlighting key milestones such as completing their Ph.D. and M.S. degrees, undertaking postdoctoral programs, and their tenure as both assistant and associate researchers. This timeline provides a comprehensive overview of their research trajectory and contributions to the field.
